false
0001468929
0001468929
2023-11-13
2023-11-13
0001468929
NXGL:CommonStockParValue0.001Member
2023-11-13
2023-11-13
0001468929
NXGL:WarrantsToPurchaseCommonStockMember
2023-11-13
2023-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 13, 2023
NEXGEL,
INC. |
(Exact
name of registrant as specified in its charter) |
Delaware |
|
001-41173 |
|
26-4042544 |
(State
or other jurisdiction |
|
(Commission
|
|
(IRS
Employer |
of
incorporation) |
|
File Number) |
|
Identification
No.) |
2150
Cabot Boulevard West, Suite B
Langhorne,
Pennsylvania |
|
19067 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (215) 702-8550
(Former
name or former address, if changed since last report)
Not
Applicable
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which
registered |
Common
Stock, par value $0.001 |
|
NXGL |
|
The
Nasdaq Capital Market LLC |
Warrants
to Purchase Common Stock |
|
NXGLW |
|
The
Nasdaq Capital Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02 | Results
of Operations and Financial Condition |
On
November 13, 2023, NexGel, Inc. (the “Company”) issued a press release reporting the Company’s results
for the quarter ended September 30, 2023, a copy of which is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
The
information in Item 2.02 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished
and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item
9.01 |
Financial
Statements and Exhibits. |
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: November 13, 2023 |
|
|
|
|
|
|
NEXGEL,
INC. |
|
|
|
|
By: |
/s/
Adam Levy |
|
|
Adam
Levy |
|
|
Chief
Executive Officer |
Exhibit
99.1
NEXGEL
Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year
Gross
profit margin improved sequentially to 28.2% in Q3 as compared to 15.0% in Q2
LANGHORNE,
Pa. – November 13, 2023 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”),
a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its
financial results for the third quarter ended September 30, 2023.
Adam
Levy, NEXGEL’s Chief Executive Officer, commented, “We are pleased to deliver yet another record revenue quarter of $1.2
million, an increase of 115% year-over-year, driven by growth year-over-year in both contract manufacturing and branded consumer products.
Importantly, gross margins during the third quarter improved sequentially to 28.2% as compared to 15.0% in the prior second quarter.
Our net loss also continued to trend lower quarter-over-quarter, in line with our goal to become profitable in 2024.”
Mr.
Levy continued, “We have a lot to be excited about as we near the close of 2023 and head into the new year. Given our growth into
retail with Enigma Health as well as partnerships with AbbVie and others, we have strategically invested in inventory and equipment to
increase capacity and automation to meet the significant increase in demand we expect for our proprietary hydrogels. We expect our revenue
growth year-over-year, margin expansion and net loss decrease trend to continue in the short term as we optimize our operations and growth
opportunities come to fruition.”
Operational
Highlights in 2023
| ● | NEXGEL’s
subsidiary, CG Converting and Packaging, executed a new supply agreement with AbbVie (NYSE:
ABBV), a global biopharmaceutical company to be a supplier of gel pads with AbbVie’s
Rapid Acoustic Pulse device being investigated for improvement in the appearance of cellulite. |
| ● | Announced
a new strategic relationship with Enigma Health, a new joint venture company, for retail
distribution and marketing services in North America. |
Third
Quarter 2023 Financial Highlights
For
the third quarter of 2023, revenue totaled $1.2 million, an increase of $653 thousand or 115%, as compared to $568 thousand for the same
period the year prior. The quarterly increase in overall revenues was primarily due to sales growth in contract manufacturing and branded
products year-over-year, including revenue contribution from the joint venture formed with C.G. Laboratories.
Gross
profit for the third quarter of 2023 was $344 thousand, compared to a gross profit of $148 thousand for the same prior year period. Gross
profit margin for the third quarter of 2023 was 28.2% as compared to 26.1% for the same period the year prior. Gross profit margin increased
sequentially to 28.2% during the third quarter of 2023 as compared to 15.0% during the second quarter of 2022.
Total
operating expenses, including R&D and SG&A expenses, decreased to $956 thousand for the three months ended September 30, 2023,
compared to $1,185 thousand for the prior year period. The year-over-year decrease was attributable to a decrease in total SG&A and
the completion of development efforts of two proof of concept studies for drug delivery candidates utilizing our hydrogel technology.
Net
loss for the quarter ended September 30, 2023, improved to $550 thousand or $0.10 per basic and diluted share, compared to net loss of
$1.2 million or $0.22 per basic and diluted share for the same period in 2022. Net loss also improved sequentially to $550 thousand during
the third quarter of 2023 as compared to $642 thousand during the second quarter of 2023.
As
of September 30, 2023, NEXGEL had approximately $3.3 million of cash. The delta between our improved net loss during the quarter and
net cash decrease period over period relates to an increase in account receivables, and property, plant and equipment investments.
As
of November 13, 2023, NEXGEL had 5,717,629 shares of common stock outstanding.
NEXGEL
Third Quarter 2023 Financial Results Conference Call
Management
will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss its operational and financial results for the third
quarter 2023.
Date:
November 13, 2023
Time:
4:30 P.M. ET
Live
Call: +1-877-407-9208 (U.S. Toll Free) or +1-201-493-6784 (International)
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1640412&tp_key=d1c55ca731
For
interested individuals unable to join the conference call, a replay will be available through November 27, 2023, at +1-844-512-2921 (U.S.
Toll Free) or +1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 13742264. An
archived version of the webcast will also be available on NEXGEL’s Investor Relations site: https://ir.nexgel.com/.
About
NEXGEL, INC.
NEXGEL
is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa.,
the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners,
NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long
periods of time with little to no irritation.
Forward-Looking
Statement
This
press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part
of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,”
“anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,”
“prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,”
“should,” “would,” “may,” and “could,” are generally forward-looking in nature and not
historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the
Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or
achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements,
whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s
forward-looking statements, please see the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, including
but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed
at http://www.sec.gov/.
Investor
Contacts:
Valter
Pinto, Managing Director
KCSA
Strategic Communications
212.896.1254
valter@kcsa.com
NEXGEL,
INC
CONDENSED
CONSOLIDATED BALANCE SHEETS
AS
OF SEPTEMBER 30, 2023 AND DECEMBER 31, 2022
(Unaudited)
(in
thousands, except share and per share data)
| |
September
30,
2023 | | |
December
31,
2022 | |
ASSETS: | |
| | | |
| | |
Current Assets: | |
| | | |
| | |
Cash | |
$ | 3,266 | | |
$ | 1,101 | |
Marketable securities | |
| - | | |
| 5,508 | |
Accounts receivable, net | |
| 1,158 | | |
| 222 | |
Inventory | |
| 1,090 | | |
| 502 | |
Prepaid expenses and other current assets | |
| 367 | | |
| 172 | |
Total current assets | |
| 5,881 | | |
| 7,505 | |
Goodwill | |
| 311 | | |
| 311 | |
Intangibles, net | |
| 12 | | |
| 20 | |
Property and equipment, net | |
| 1,737 | | |
| 721 | |
Operating lease - right of use asset | |
| 1,911 | | |
| 1,737 | |
Other assets | |
| 95 | | |
| 63 | |
Total assets | |
$ | 9,947 | | |
$ | 10,357 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
Current Liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 1,073 | | |
$ | 265 | |
Accrued expenses and other current liabilities | |
| 152 | | |
| 130 | |
Deferred revenue | |
| 34 | | |
| - | |
Current portion of note payable | |
| 5 | | |
| 15 | |
Warrant liability | |
| 146 | | |
| 242 | |
Operating lease liability, current portion | |
| 233 | | |
| 207 | |
Total current liabilities | |
| 1,643 | | |
| 859 | |
Operating lease liability, net of current portion | |
| 1,774 | | |
| 1,593 | |
Notes payable, net of current portion | |
| 274 | | |
| 268 | |
Total liabilities | |
| 3,691 | | |
| 2,720 | |
| |
| | | |
| | |
Commitments and Contingencies (Note 15) | |
| | | |
| | |
| |
| | | |
| | |
STOCKHOLDERS’ EQUITY | |
| | | |
| | |
Preferred stock, par value $0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding | |
| - | | |
| - | |
Common stock, par value $0.001 per share, 25,000,000 shares authorized; 5,717,629 and 5,577,916 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively | |
| 6 | | |
| 6 | |
Additional paid-in capital | |
| 19,309 | | |
| 19,189 | |
Accumulated deficit | |
| (13,617 | ) | |
| (11,558 | ) |
Total NexGel stockholders’ equity | |
| 5,698 | | |
| 7,637 | |
Non-controlling interest in joint venture | |
| 558 | | |
| - | |
Total stockholders’ equity | |
| 6,256 | | |
| 7,637 | |
Total liabilities and stockholders’ equity | |
$ | 9,947 | | |
$ | 10,357 | |
NEXGEL,
INC.
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR
THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022
(Unaudited)
(in
thousands, except share and per share data)
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenues, net | |
$ | 1,221 | | |
$ | 568 | | |
$ | 3,007 | | |
$ | 1,524 | |
| |
| | | |
| | | |
| | | |
| | |
Cost of revenues | |
| 877 | | |
| 420 | | |
| 2,546 | | |
| 1,304 | |
| |
| | | |
| | | |
| | | |
| | |
Gross profit | |
| 344 | | |
| 148 | | |
| 461 | | |
| 220 | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses | |
| | | |
| | | |
| | | |
| | |
Research and development | |
| 6 | | |
| 193 | | |
| 90 | | |
| 328 | |
Selling, general and administrative | |
| 950 | | |
| 992 | | |
| 2,629 | | |
| 2,459 | |
Total operating expenses | |
| 956 | | |
| 1,185 | | |
| 2,719 | | |
| 2,787 | |
| |
| | | |
| | | |
| | | |
| | |
Loss from operations | |
| (612 | ) | |
| (1,037 | ) | |
| (2,258 | ) | |
| (2,567 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income (expense) | |
| | | |
| | | |
| | | |
| | |
Interest expense | |
| (3 | ) | |
| (242 | ) | |
| (13 | ) | |
| (1,334 | ) |
Interest income | |
| 1 | | |
| - | | |
| 3 | | |
| - | |
Loss on debt extinguishment | |
| - | | |
| - | | |
| - | | |
| (150 | ) |
Warrant modification expense | |
| - | | |
| (57 | ) | |
| - | | |
| (57 | ) |
Other income | |
| - | | |
| - | | |
| 3 | | |
| 2 | |
Gain on investments | |
| 44 | | |
| 5 | | |
| 168 | | |
| 5 | |
Changes in fair value of warrant liability | |
| 18 | | |
| 104 | | |
| 96 | | |
| 3 | |
Total other income (expense), net | |
| 60 | | |
| (190 | ) | |
| 257 | | |
| (1,531 | ) |
Loss before income taxes | |
| (552 | ) | |
| (1,227 | ) | |
| (2,001 | ) | |
| (4,098 | ) |
Income tax expense | |
| - | | |
| - | | |
| - | | |
| - | |
Net loss | |
$ | (552 | ) | |
$ | (1,227 | ) | |
$ | (2,001 | ) | |
$ | (4,098 | ) |
Less: (Income) loss attributable to non-controlling interest in joint venture | |
| 2 | | |
| - | | |
| (58 | ) | |
| - | |
Net loss attributable to NexGel stockholders | |
| (550 | ) | |
| (1,227 | ) | |
| (2,059 | ) | |
| (4,098 | ) |
Net loss per common share - basic | |
$ | (0.10 | ) | |
$ | (0.22 | ) | |
$ | (0.36 | ) | |
$ | (0.74 | ) |
Net loss per common share - diluted | |
$ | (0.10 | ) | |
$ | (0.22 | ) | |
$ | (0.36 | ) | |
$ | (0.74 | ) |
Weighted average shares used in computing net loss per common share - basic | |
| 5,714,316 | | |
| 5,572,234 | | |
| 5,654,981 | | |
| 5,572,234 | |
Weighted average shares used in computing net loss per common share – diluted | |
| 5,714,316 | | |
| 5,572,234 | | |
| 5,654,981 | | |
| 5,572,234 | |
NEXGEL,
INC.
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR
THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022
(Unaudited)
(in
thousands)
| |
Nine Months Ended September 30, | |
| |
2023 | | |
2022 | |
Operating Activities | |
| | | |
| | |
Net loss | |
$ | (2,059 | ) | |
$ | (4,098 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Income attributable to non-controlling interest in joint venture | |
| 58 | | |
| - | |
Depreciation and amortization | |
| 103 | | |
| 84 | |
Changes in ROU asset and operating lease liability | |
| 33 | | |
| 29 | |
Share-based compensation and restricted stock vesting | |
| 120 | | |
| 231 | |
Gain on investment in marketable securities | |
| 168 | | |
| (5 | ) |
Changes in fair value of warrant liability and warrant modification | |
| (96 | ) | |
| (3 | ) |
Amortization of deferred financing costs | |
| - | | |
| 1,325 | |
Warrant modification expense | |
| - | | |
| 57 | |
Loss on extinguishment of debt | |
| - | | |
| 150 | |
| |
| | | |
| | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Accounts receivable | |
| (936 | ) | |
| (56 | ) |
Inventory | |
| (588 | ) | |
| (108 | ) |
Prepaid expenses and other assets | |
| (227 | ) | |
| (162 | ) |
Accounts payable | |
| 808 | | |
| 104 | |
Accrued expenses and other current liabilities | |
| (67 | ) | |
| 109 | |
Deferred revenue | |
| 34 | | |
| - | |
Net Cash Used in Operating Activities | |
| (2,649 | ) | |
| (2,343 | ) |
| |
| | | |
| | |
Investing Activities | |
| | | |
| | |
Proceeds from sales of marketable securities | |
| 5,340 | | |
| 1,000 | |
Investment in marketable securities | |
| - | | |
| (6,980 | ) |
Capital expenditures | |
| (611 | ) | |
| (88 | ) |
Net Cash Provided by (Used in) Investing Activities | |
| 4,729 | | |
| (6,068 | ) |
| |
| | | |
| | |
Financing Activities | |
| | | |
| | |
Proceeds from margin line of credit | |
| 89 | | |
| - | |
Principle payments of notes payable | |
| (4 | ) | |
| (3,512 | ) |
Net Cash Provided by (Used in) Financing Activities | |
| 85 | | |
| (3,512 | ) |
Net Increase (Decrease) in Cash | |
| 2,165 | | |
| (11,923 | ) |
Cash – Beginning of period | |
| 1,101 | | |
| 13,350 | |
Cash – End of period | |
$ | 3,266 | | |
$ | 1,427 | |
Supplemental Disclosure of Cash Flows Information | |
| | | |
| | |
Cash paid during the year for: | |
| | | |
| | |
Interest | |
$ | 7 | | |
$ | - | |
Taxes | |
$ | - | | |
$ | - | |
| |
| | | |
| | |
Supplemental Non-cash Investing and Financing activities | |
| | | |
| | |
Property and equipment contributed as capital investment to JV | |
$ | 500 | | |
$ | - | |
ROU asset and operating lease liabilities recognized upon consolidation of JV | |
$ | 334 | | |
$ | - | |
v3.23.3
Cover
|
Nov. 13, 2023 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 13, 2023
|
Entity File Number |
001-41173
|
Entity Registrant Name |
NEXGEL,
INC.
|
Entity Central Index Key |
0001468929
|
Entity Tax Identification Number |
26-4042544
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
2150
Cabot Boulevard West
|
Entity Address, Address Line Two |
Suite B
|
Entity Address, City or Town |
Langhorne
|
Entity Address, State or Province |
PA
|
Entity Address, Postal Zip Code |
19067
|
City Area Code |
(215)
|
Local Phone Number |
702-8550
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common Stock, par value $0.001 |
|
Title of 12(b) Security |
Common
Stock, par value $0.001
|
Trading Symbol |
NXGL
|
Security Exchange Name |
NASDAQ
|
Warrants to Purchase Common Stock |
|
Title of 12(b) Security |
Warrants
to Purchase Common Stock
|
Trading Symbol |
NXGLW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=NXGL_CommonStockParValue0.001Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=NXGL_WarrantsToPurchaseCommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
NexGel (NASDAQ:NXGL)
Historical Stock Chart
From Apr 2024 to May 2024
NexGel (NASDAQ:NXGL)
Historical Stock Chart
From May 2023 to May 2024